Imaging B cell maturation antigen in multiple myeloma
Open Access
- 30 June 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (18)
Abstract
Multiple myeloma is a systemic and spatially heterogeneous cancer of plasma cells. Available methods for diagnosing and monitoring disease do not fully capture its heterogeneity. For instance, bone marrow sampling is anatomically limited and [ 18 F]FDG PET/CT reflects glucose metabolism rather than a specific target. In this issue of JCI , Gu et al. reported a prospective phase I study of [ 68 Ga]Ga-PFBC01, a nanobody tracer targeting B cell maturation antigen (BCMA). The study presents a coherent translational pathway for [ 68 Ga]Ga-PFBC01 PET and demonstrates high sensitivity, associations with tissue and circulating disease measures, and clinical management impact. By shifting myeloma imaging from metabolic assessment toward target biology, [ 68 Ga]Ga-PFBC01 PET may visualize whole-body disease distribution and actionable target expression, while blood-pool activity may reflect systemic antigen biology (Figure 1).Keywords
This publication has 19 references indexed in Scilit:
- BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escapeSeminars in Hematology, 2025
- Opportunities and challenges for MRD assessment in the clinical management of multiple myelomaNature Reviews Clinical Oncology, 2025
- Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaLeukemia, 2025
- Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaNature Medicine, 2023
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021
- Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myelomaAnnals of Hematology, 2020
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyThe Lancet Oncology, 2020
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencingNature Communications, 2017
- Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupThe Lancet Oncology, 2017
- γ-secretase directly sheds the survival receptor BCMA from plasma cellsNature Communications, 2015